Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer [14]

Matthias D. Hofer*, Mark A. Rubin

*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer [14]'. Together they form a unique fingerprint.